Literature DB >> 30080747

Unravelling the GSK3β-related genotypic interaction network influencing hippocampal volume in recurrent major depressive disorder.

Becky Inkster1,2,3, Andy Simmons4, James H Cole4,5, Erwin Schoof6, Rune Linding6, Tom Nichols7, Pierandrea Muglia8, Florian Holsboer9, Philipp G Sämann9, Peter McGuffin4, Cynthia H Y Fu4, Kamilla Miskowiak10, Paul M Matthews11, Gwyneth Zai12,13, Kristin Nicodemus14,15.   

Abstract

OBJECTIVE: Glycogen synthase kinase 3β (GSK3β) has been implicated in mood disorders. We previously reported associations between a GSK3β polymorphism and hippocampal volume in major depressive disorder (MDD). We then reported similar associations for a subset of GSK3β-regulated genes. We now investigate an algorithm-derived comprehensive list of genes encoding proteins that directly interact with GSK3β to identify a genotypic network influencing hippocampal volume in MDD. PARTICIPANTS AND METHODS: We used discovery (N=141) and replication (N=77) recurrent MDD samples. Our gene list was generated from the NetworKIN database. Hippocampal measures were derived using an optimized Freesurfer protocol. We identified interacting single nucleotide polymorphisms using the machine learning algorithm Random Forest and verified interactions using likelihood ratio tests between nested linear regression models.
RESULTS: The discovery sample showed multiple two-single nucleotide polymorphism interactions with hippocampal volume. The replication sample showed a replicable interaction (likelihood ratio test: P=0.0088, replication sample; P=0.017, discovery sample; Stouffer's combined P=0.0007) between genes associated previously with endoplasmic reticulum stress, calcium regulation and histone modifications.
CONCLUSION: Our results provide genetic evidence supporting associations between hippocampal volume and MDD, which may reflect underlying cellular stress responses. Our study provides evidence of biological mechanisms that should be further explored in the search for disease-modifying therapeutic targets for depression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30080747      PMCID: PMC6531290          DOI: 10.1097/YPG.0000000000000203

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  58 in total

1.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

2.  Systematic discovery of in vivo phosphorylation networks.

Authors:  Rune Linding; Lars Juhl Jensen; Gerard J Ostheimer; Marcel A T M van Vugt; Claus Jørgensen; Ioana M Miron; Francesca Diella; Karen Colwill; Lorne Taylor; Kelly Elder; Pavel Metalnikov; Vivian Nguyen; Adrian Pasculescu; Jing Jin; Jin Gyoon Park; Leona D Samson; James R Woodgett; Robert B Russell; Peer Bork; Michael B Yaffe; Tony Pawson
Journal:  Cell       Date:  2007-06-14       Impact factor: 41.582

Review 3.  The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

Authors:  C A Grimes; R S Jope
Journal:  Prog Neurobiol       Date:  2001-11       Impact factor: 11.685

4.  Family history of depression is associated with younger age of onset in patients with recurrent depression.

Authors:  F Tozzi; I Prokopenko; J D Perry; J L Kennedy; A D McCarthy; F Holsboer; W Berrettini; L T Middleton; H D Chilcoat; P Muglia
Journal:  Psychol Med       Date:  2008-02-13       Impact factor: 7.723

5.  Association analysis of HSP90B1 with bipolar disorder.

Authors:  Chihiro Kakiuchi; Mizuho Ishiwata; Shinichiro Nanko; Hiroshi Kunugi; Yoshio Minabe; Kazuhiko Nakamura; Norio Mori; Kumiko Fujii; Tadashi Umekage; Mamoru Tochigi; Kazuhisa Kohda; Tsukasa Sasaki; Kazuo Yamada; Takeo Yoshikawa; Tadafumi Kato
Journal:  J Hum Genet       Date:  2007-09-04       Impact factor: 3.172

6.  Measuring depression: comparison and integration of three scales in the GENDEP study.

Authors:  R Uher; A Farmer; W Maier; M Rietschel; J Hauser; A Marusic; O Mors; A Elkin; R J Williamson; C Schmael; N Henigsberg; J Perez; J Mendlewicz; J G E Janzing; A Zobel; M Skibinska; D Kozel; A S Stamp; M Bajs; A Placentino; M Barreto; P McGuffin; K J Aitchison
Journal:  Psychol Med       Date:  2007-10-09       Impact factor: 7.723

7.  Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder.

Authors:  Chihiro Kakiuchi; Kazuya Iwamoto; Mizuho Ishiwata; Miki Bundo; Takaoki Kasahara; Ichiro Kusumi; Takahiro Tsujita; Yuji Okazaki; Shinichiro Nanko; Hiroshi Kunugi; Tsukasa Sasaki; Tadafumi Kato
Journal:  Nat Genet       Date:  2003-08-31       Impact factor: 38.330

8.  Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts.

Authors:  P Muglia; F Tozzi; N W Galwey; C Francks; R Upmanyu; X Q Kong; A Antoniades; E Domenici; J Perry; S Rothen; C L Vandeleur; V Mooser; G Waeber; P Vollenweider; M Preisig; S Lucae; B Müller-Myhsok; F Holsboer; L T Middleton; A D Roses
Journal:  Mol Psychiatry       Date:  2008-12-23       Impact factor: 15.992

9.  Aberrant endoplasmic reticulum stress response in lymphoblastoid cells from patients with bipolar disorder.

Authors:  Akiko Hayashi; Takaoki Kasahara; Mizue Kametani; Tomoko Toyota; Takeo Yoshikawa; Tadafumi Kato
Journal:  Int J Neuropsychopharmacol       Date:  2008-09-04       Impact factor: 5.176

10.  Association of X-box binding protein 1 ( XBP1) genotype with morning cortisol and 1-year clinical course after a major depressive episode.

Authors:  Michael F Grunebaum; Hanga C Galfalvy; Yung-yu Huang; Thomas B Cooper; Ainsley K Burke; Melissa Agnello; Maria A Oquendo; J John Mann
Journal:  Int J Neuropsychopharmacol       Date:  2009-01-20       Impact factor: 5.176

View more
  1 in total

Review 1.  GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?

Authors:  Becky Inkster; Gwyneth Zai; Gemma Lewis; Kamilla W Miskowiak
Journal:  Transl Psychiatry       Date:  2018-10-11       Impact factor: 6.222

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.